Danaher (DHR) Stock
Diversified science company for life sciences and diagnostics. Here's the price, business snapshot, and what's worth knowing about Danaher in July 2026.
Danaher Corporation (DHR) is a diversified science and technology company focused on life sciences, diagnostics and environmental & applied solutions. It supplies instruments, consumables, software and services used by research laboratories, hospitals and industrial customers worldwide. With a market capitalisation of about $155.94 billion, Danaher combines organic R&D-driven growth with disciplined acquisitions and operational rigor (the Danaher Business System) to drive recurring revenue and margin expansion. Investors often watch its exposure to healthcare spending, diagnostic cycles and capital-equipment demand. Strengths include a broad product portfolio, strong cash generation and a track record of integrating acquisitions; risks include execution on M&A, regulatory changes, cyclicality in capital spending and currency swings. Valuation can be premium given its defensive characteristics, but future returns are uncertain. This is general educational information, not personal investment advice — consider your goals and consult an authorised adviser before making investment decisions.
Why It’s Moving
DHR Stock Surges as Analysts Cite Strong Q3 Momentum and Healthcare Sector Resilience for 2027 Outlook
- [•] Third-quarter earnings beat analyst forecasts by a notable margin, with revenue growth of 5.9% pointing to accelerated adoption of AI-enabled diagnostic tools in clinical settings.
- [•] Management highlighted a strategic expansion in its cardiovascular division, revealing new regulatory approvals that are expected to unlock a fresh revenue stream in the coming fiscal year.
- [•] The broader healthcare sector is displaying resilience against inflationary pressures, with Danaher's diversified business model shielding it from commodity cost volatility and maintaining its competitive rating of 'Strong Buy'.
DHR Stock Surges as Analysts Cite Strong Q3 Momentum and Healthcare Sector Resilience for 2027 Outlook
- [•] Third-quarter earnings beat analyst forecasts by a notable margin, with revenue growth of 5.9% pointing to accelerated adoption of AI-enabled diagnostic tools in clinical settings.
- [•] Management highlighted a strategic expansion in its cardiovascular division, revealing new regulatory approvals that are expected to unlock a fresh revenue stream in the coming fiscal year.
- [•] The broader healthcare sector is displaying resilience against inflationary pressures, with Danaher's diversified business model shielding it from commodity cost volatility and maintaining its competitive rating of 'Strong Buy'.
When is the next earnings date for Danaher (DHR)?
Based on historical reporting schedules and available estimates, Danaher Corporation (DHR) is expected to release its next earnings report on Tuesday, July 21, 2026. This upcoming announcement will cover the financial results for the second quarter of 2026. The company has not yet confirmed an official date, but this timing aligns with its typical quarterly release pattern. Investors should monitor official company communications for any final confirmation or conference call details.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Danaher’s stock with a target price of $258.58, indicating growth potential.
Financial Health
Danaher is performing well with strong revenue and cash flow, indicating a healthy financial position.
Dividend
Danaher's dividend yield of 0.69% is relatively low, indicating limited income potential. If you invested $1000 you would be paid $6.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring DHR
Pharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published: 21 December 2025
Explore BasketHealthcare Innovation Brazil Investment Theme 2025
Brazil is ramping up investment to enhance its healthcare quality and access, creating significant opportunities for innovation. This basket offers exposure to key US and EU-listed companies providing the medical devices, software, and biotech research driving this transformation.
Published: 30 October 2025
Explore BasketBrazil Water Stocks (Infrastructure & Tech Leaders)
Brazil is undertaking a massive multi-billion dollar overhaul of its water systems to improve public health and the environment for millions. This basket offers exposure to global leaders in water technology, pumps, and infrastructure that may be positioned to support this nationwide upgrade.
Published: 23 October 2025
Explore BasketUS Conglomerates: Could They Diversify Your Portfolio?
Brazilian investors may find opportunities to reduce portfolio volatility tied to the domestic economy through time-tested, multi-sector business models. This basket provides exposure to a selection of large-cap, US-listed conglomerates with diversified global operations.
Published: 20 October 2025
Explore BasketHealthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: 14 October 2025
Explore BasketActivist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: 11 August 2025
Explore BasketAcquirer's Engine
Invest in companies with proven expertise in growth-by-acquisition. These carefully selected stocks represent businesses with exceptional management teams that consistently buy their way to market leadership and enhanced profitability through strategic M&A.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Revenue Engine
Consumables and service contracts support predictable recurring revenue and cash flow, though demand can vary with spending cycles.
Global Healthcare Reach
A broad international footprint offers diversification across markets, while currency moves and regional regulation remain potential headwinds.
Innovation & M&A
R&D and targeted acquisitions expand capabilities and addressable markets, but integration and valuation risks deserve attention.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
